In the in vitro model of Alzheimer's disease and in APP/PS1 mice, the administration of TAT‐CAPONi reduced nNOS–CAPON interaction (Figure 1b, p < .05). This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.